{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 42 of 92', 'CR845-CLIN3102', 'Table 2.', 'Schedule of Events: Double-blind Phase (Continued)', 'Study Procedures', 'Double-blind End of', 'Screening', 'Run-in', 'Treatmentb/', 'Discontinuation', 'Visit9', 'Period9', 'Double-blind Treatment Period', 'Early Termination', 'Period', 'Day -28 to', 'Day -7 to', 'First Day of', 'Day -7', 'Day 1', 'Week 1', 'Week 2 to 12', 'Week 13', 'DP Days 2b -14', 'Visit Days', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 98', '15', '17', '19', '22', '24', '26', '29\"', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57th', '59', '61', '64', '66', '68', '71th', '73', '75', '78', '80', '82', 'Safety and efficacy evaluations', 'Patient training on PRO worksheets', 'Xhij', 'X\u00b9', 'Worst Itching Intensity NRS (daily)k', 'x', 'Record on an ongoing basis', 'X', 'Skindex-10 Scale, 5-D Itch Scalem', 'Xm', 'Xm', 'Patient Global Impression of Change', 'X', 'Patient Health Assessment (ShOWS) and', 'Observer Health Assessment (OOWS)', 'XX', 'XX', 'worksheets', 'Record dose of ESA and IV iron', 'Record on an ongoing basis', 'X', 'Record number of missed dialysis visits and', 'Record on an ongoing basis', 'reason(s)', 'IV administration of study drug', 'Record on an ongoing basis', 'Inflammatory biomarker samples\u00b0', 'X', 'X', 'Adverse event monitoring', 'X', 'X', 'Record on an ongoing basis', 'X', 'X', 'Concomitant medications (including antipruritic', 'medications)', 'Record on an ongoing basis', 'X', 'X', 'Structured Safety Evaluation', 'X', 'X', 'X', 'DP = Discontinuation Period; ESA = erythropoiesis-stimulating agent; F = Friday, IV = intravenous; M = Monday; NRS = numerical rating scale; OOWS = Objective Opiate Withdrawal Scale;', 'PRO = patient-reported outcome; Sa = Saturday, ShOWS = Short Opiate Withdrawal Scale; Th = Thursday, Tu = Tuesday, W = Wednesday', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 44 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 43 of 92', 'CR845-CLIN3102', 'a.', \"Each visit during the Double-blind Treatment Period will coincide with the patient's normal dialysis treatments.\", 'b. The End-of-Treatment Visit in the Double-blind Phase will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 13 [Day 85]), which also corresponds to Day 1', 'of the Discontinuation Period (DP Day 1).', 'c.', 'Medical history will be updated on Day 1 with any changes since the Screening Visit, and inclusion/exclusion criteria will be confirmed prior to randomization. Antipruritic medication will be', 'updated at each dialysis visit during the Run-in Period.', 'd.', 'Electrocardiogram must be performed prior to the start of dialysis at screening, Day 85 (End of Treatment), or at Early Termination visit.', 'e.', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded on Days 1, 15, 29, 43, 57, 71 and 85 (End of Treatment), or at Early Termination visit only', 'when the patient is in a sitting or semi-recumbent position. Heart rate will be measured at each dialysis; if heart rate is clinically significant and outside the prespecified visits per Schedule of', 'Events, the heart rate will be recorded on the relevant CRF page.', 'f.', 'Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded at each dialysis visit during the Discontinuation Period. Heart rate will be measured at each', 'dialysis.', 'g.', 'Blood samples for clinical laboratory evaluation will be taken at screening, and on Days 1 and 85 (End of Treatment), or at Early Termination', 'visit', 'only.', 'h.', 'Training on Worst Itching Intensity NRS will be conducted on the first day of the Run-in Period (Day -7).', 'i.', 'Training on ShOWS on Day -7 and first day of Week 13.', 'j.', 'Training on Skindex-10 Scale and 5-D Itch Scale may be performed at any time during the week prior to randomization or on Day 1 of the Double-blind Treatment Period', 'k.', 'Patients will be requested to complete their Worst Itching Intensity NRS worksheets each day at a similar time (either at home on non-dialysis days around the normal start time of their dialysis or', 'in the dialysis unit). On dialysis days, the worksheets will be completed prior to or during dialysis, but must be completed prior to dosing.', 'l. During the Discontinuation Period, Worst Itching Intensity NRS worksheets will be completed on dialysis days only.', 'm.', '5-D Itch Scale and Skindex-10 Scale completed on Day 1 and the first visit of Weeks 5, 9 and 11 (on Days 29, 57 and 71) and Week 13 (Day 85). 5-D Itch scale will preferably be completed first.', 'If the first visit of the week is missed, the patient may complete the worksheets at their next visit for the same week. The worksheets will be completed prior to or during dialysis (preferably within', '1 hour of the dialysis), but must be completed prior to dosing.', 'n.', 'ShOWS worksheets will be completed daily through the entire Discontinuation Period starting on Day 85. The OOWS worksheets will be completed at each dialysis visit during the', 'Discontinuation Period starting on Day 85. On the day of a dialysis visit, the OOWS and the ShOWS will be completed during the first hour (+1-hour window allowed) of dialysis so that dialysis-', 'associated patient fatigue and other potential side effects related to the dialysis procedure should minimally interfere with the', 'completion', 'of', 'the', 'scales.', 'o.', 'Biomarker samples must be collected prior to the start of dialysis on Day 1 and Day 85.', 'p', 'Concomitant medications including antipruritic medication will be updated at each dialysis visit during the Double-blind Treatment Period, and until the end of the Discontinuation Period.', 'q.', 'Sites have the option to conduct the Screening Visit during the Run-in Period at the discretion of the Investigator', 'r.', 'A list of specific signs/symptoms will be verified with the patient by qualified site staff, preferably to be completed on Wednesday/Thursday each week during the Run-in Period, the Double-blind', 'Treatment Period and the Discontinuation Period. Not to be completed on Monday/Tuesday.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 45 of 95']\n\n###\n\n", "completion": "END"}